Abstract. miR-30a is situated on chromosome 6q.13 and is produced by an intronic transcriptional unit. However, its role in regulating the apoptosis, invasion and metastasis of breast cancer cells is not yet fully understood. The aim of this study was to research the biological function of miR-30a and its direct target gene in breast cancer. The biological function of miR-30a was determined by examining breast cancer cell growth, apoptosis, metastasis and invasion. In addition, Notch1 expression was measured by western blot analysis, and a luciferase reporter vector was constructed to identify the miR-30a target gene. miR-30a was found to be significantly downregulated in breast cancer cells. We also found that miR-30a inhibited breast cancer cell viability, migration and invasion, and induced cell apoptosis. On the whole, our data indicate that miR-30a attenuates the development of breast cancer by regulating the expression of the downstream target gene, Notch1.

Introduction

Breast cancer is the most common type of cancer affecting women and a leading cause of mortality for females worldwide (1,2). However, several studies have reported that microRNAs (miRNAs or miRs) are involved in regulating gene expression, as well as regulating diverse physiological and pathological processes (3,4). miRNAs are short, highly conserved small non-coding RNA molecules of 19-25 nucleotides in length that regulate gene expression at the post-transcriptional level. By targeting complementary binding sites within the 3' untranslated region (3'UTR) of target messenger RNAs (mRNAs), they impair or inhibit translation and promote degradation (5-8). Similarly, miR-30a is situated on chromosome 6q.13 and is produced by an intronic transcriptional unit (9,10). Two mature forms of miR-30a exist, miR-30a-3p and miR-30a-5p. miR-30a is deregulated in several malignant tumors, such as breast cancer (11), hepatocellular cancer (12), colon cancer (13), nasopharyngeal carcinoma (14), prostate cancer (15), endometrial cancer (16) and cutaneous squamous cell carcinoma (17). Moreover, miR-30a has been shown to be a potential prognostic marker in breast cancer (18).

The Notch signaling pathway is highly conserved and plays an important role in intercellular signaling and developmental processes; it includes NOTCH ligands (JAG1, JAG2, DLL1, DLL3 and DLL4) (19,20), Notch receptors (Notch1, -2, -3 and -4), and the downstream target genes, hairy and enhancer of split-1 (HES1) and cyclin D1, and FADD-like apoptosis regulator (CFLAR) (21‑23). Previous studies have confirmed that the overexpression of Notch1 is associated with cancer, particularly breast cancer, cancer cell proliferation and apoptosis, as well as the promotion of migration and invasion (24,25).

However, the function and mechanisms of action of miR-30a in breast cancer are not yet fully understood, nor is its association with the Notch1 target gene. Thus, in this study, we aimed to shed light into this matter. We propose a logical hypothesis: miR-30a may mediate Notch1, and thus regulating its biological function.

Materials and methods

Cell culture. The human breast cancer cell lines, MCF-7 and MDA-MB-231, were purchased from the American Type Culture Collection (ATCC, Rockville, MD, USA). All cell lines were cultured in RPMI-1640 (Keygen, Nanjing China), supplemented with 10% fetal bovine serum (FBS; Gibco-Life Technologies, Carlsbad, CA, USA) and kept in a humidified atmosphere containing 5% CO₂ at 37°C.

Cell transfection. Human hsa-miR-30a mimic and hsa-miR negative control were purchased from Gene Pharma (Shanghai, China). Small interfering RNA (siRNA) against human Notch1 (si-Notch1), negative control siRNA (NC-siRNA) and si-h-GAPDH were purchased from RiboBio Co., Guangzhou, China. At 24 h prior to transfection, the MCF-7 and
MDA-MB-231 cells were plated in 6-well plates (2.5×10^5 cells/well), and then transfected with miR-30a mimic (at 100 nM final concentration; GenePharma), or miR negative control (100 nM; GenePharma) using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). NC-siRNA at 100 nM, si-Notch1 or si-h-GAPDH were delivered into the cells following the manufacturer's instructions. The cells transfected with the miRNA mimic or siRNA were harvested 12-48 h post-transfection.

**Reverse transcription-quantitative PCR (RT-qPCR).** Total RNA was extracted using TRIzol® reagent (Invitrogen). RT-PCR was carried out using the TaqMan® MicroRNA Reverse Transcription kit (Applied Biosystems: Life Technologies, Carlsbad, CA, USA). Mature miRNA was spotted using the TaqMan® MicroRNA assay kit (assay ID: miR-30a: 000417 and RNU6B: 001093) (Applied Biosystems; Life Technologies). All procedures were performed according to the manufacturer's instructions. The primers used were as follows: Notch1 forward, 5'-CACCTGGGGGCGGTCC-3' and reverse, 5'-GTGTATTGTTCCGACCAT-3'. Relative expression levels were calculated using the ΔΔCt method and normalized to RNU6B expression (fold difference relative to RNU6B). The quantitative analysis of the changes in expression levels were calculated using the ABI 7300 real-time PCR machine (Applied Biosystems). All reverse transcription and PCR assays were carried out in triplicate.

**Cell proliferation assay.** At 24 h following the transfection of miRNA mimics, the cells were seeded into 96-well plates (5×10^3 cells/well). Subsequently, 10 µl of cell counting kit-8 assay solution (CCK-8; Dojindo, Kumamoto Prefecture, Kyushu, Japan) were added to the cultured cells in 100 µl of culture medium and incubated in a humidified atmosphere for 1 h at 37°C; each experiment was performed in triplicate. The absorbance was measured at 570 nm using CliniBio 128 (ASYS-Hitech, Eugendorf, Austria).

**Cell apoptosis assay.** The MCF-7 and MDA-MB-231 cells were transfected with miR-30a mimic or negative control for 48 h. Subsequently, the cells were trypsinized and collected by centrifugation at 1,000 rpm for 5 min. The cell pellets were rinsed twice with ice-cold phosphate-buffered saline (PBS). Apoptosis was determined by dual staining using the FITC Annexin V apoptosis detection kit I (BD Biosciences, Franklin Lakes, NJ, USA) according to the manufacturer's instructions. The experiment was carried out in triplicate.

**Cell migration assays.** To examine cell migration, tissue culture inserts (6.5 mm diameter) with an 8.0 µm pore size (Transwell; Corning, Inc., Corning, NY, USA) were placed into the wells of 24-well culture plates, separating the upper and the lower chambers. The cells transfected with either miR-30a mimics or negative control miRNA were cultured in 6-well plates, and the cells were starved for 24 h. The cells (1×10^5 cells/well) suspended in 200 µl RPMI-1640 serum-free medium were added to the upper chamber and 600 µl RPMI-1640 medium supplemented with 20% FBS was placed into the lower chamber. Following 24 h of incubation in a humidified atmosphere, the cells that migrated through the Transwell membrane were fixed in 4% paraformaldehyde, stained with crystal violet, and 4 random fields were counted under a microscope (magnification, x100). The experiment was performed in triplicate.

**miRNA target gene identification.** The prediction of miRNA target genes was carried out using TargetScan (http://www.targetscan.org), Pictar (http://pictar.mdc-berlin.de), microRNA (http://www.microrna.org).

**Dual luciferase activity assay.** The wild-type and mutant seed region of Notch1 containing the putative target site for Pre-miR-30a was synthesized and cloned into the PGL3-promoter vector (Life Technologies). The MCF-7 cells (5×10^3 cells/well) were incubated in 24-well plates. miR-30a mimic or control mimic, PGL3-Notch1 3'UTR-WT vector or PGL3-Notch1 3'UTR-MUT vector containing Firefly luciferase reporter gene and 3'UTR of Notch1 gene (Promega, Madison, WI, USA) were co-transfected into the cells using Lipofectamine 2000 (Invitrogen). After 48 h of transfection, luciferase activity was analyzed by using the Dual Luciferase Reporter assay system (Promega) and normalized to Renilla luciferase activity.

**Western blot analysis.** Total protein was extracted and lysed using RIPA buffer (Beyotime). Equal amounts of protein were separated by NuPAGE® LDS Sample Buffer (4X) and NuPAGE® Reducing Agent (10X) (both from Life Technologies). A total of 20 µl protein from each sample was used for western blot analysis. Initially, protein samples were separated using a 5% MOPS SDS running buffer (20X) (Life Technologies), and they were subsequently transferred onto polyvinylidene difluoride membranes (Sigma, Deisenhofen, Germany). The membranes were then washed with TBST, blocked with western blocking buffer (Beyotime) and incubated with primary antibodies against human Notch1 (1:2,000; ab8925; Abcam, Cambridge, MA, USA) overnight at 4°C. The membranes were then washed with TBST and incubated with the goat anti-rabbit IgG peroxidase-conjugated secondary antibody (1:5,000; BS10650; Bioworld, Nanjing, China). The protein band was detected by chemiluminescence with Pierce ECL kits (Millipore, Billerica, MA, USA). β-actin (1:5,000; AP0060; Bioworld) was used as an internal loading control to normalize the expression patterns of each sample. Three separate experiments were performed and only representative images are shown.

**Patients and samples.** Samples were acquired from patients (n=20) who were diagnosed at the Jiangsu Cancer
Table I. Clinicopathological characteristics of 20 patients with breast cancer.

<table>
<thead>
<tr>
<th>Clinicopathologic parameters</th>
<th>No. of patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>32-60</td>
</tr>
<tr>
<td>Tumor diameter</td>
<td></td>
</tr>
<tr>
<td>T1</td>
<td>3</td>
</tr>
<tr>
<td>T2</td>
<td>15</td>
</tr>
<tr>
<td>T3</td>
<td>2</td>
</tr>
<tr>
<td>Lymph node</td>
<td></td>
</tr>
<tr>
<td>Negative</td>
<td>4</td>
</tr>
<tr>
<td>Positive</td>
<td>16</td>
</tr>
<tr>
<td>Histological-pathological types</td>
<td></td>
</tr>
<tr>
<td>Invasive ductal carcinoma</td>
<td>18</td>
</tr>
<tr>
<td>Invasive lobular carcinoma</td>
<td>2</td>
</tr>
<tr>
<td>Clinical stage</td>
<td></td>
</tr>
<tr>
<td>I-II</td>
<td>6</td>
</tr>
<tr>
<td>III</td>
<td>14</td>
</tr>
<tr>
<td>Hormone receptor</td>
<td></td>
</tr>
<tr>
<td>Negative</td>
<td>7</td>
</tr>
<tr>
<td>Positive</td>
<td>13</td>
</tr>
<tr>
<td>Her-2</td>
<td></td>
</tr>
<tr>
<td>Negative</td>
<td>9</td>
</tr>
<tr>
<td>Positive</td>
<td>11</td>
</tr>
</tbody>
</table>

Hospital, Affiliated Hospital of Nanjing Medical University, from 2012-2015 (Table I). All the patients provided written informed consent and the study was approved by the Ethics Committee of Jiangsu Cancer Hospital (Nanjing, China).

In vivo tumorigenicity. Female BALB/c nude mice were purchased from the Experimental Animal Center of the Academy of Military Sciences, China (serial no. 0027549). Female BALB/c nude mice (6-8 weeks old) were separately caged in a standard environment. MDA-MB-231 cells transfected with either the negative control or miR-30a mimic (1x10^7 cells, 0.1 ml) were injected subcutaneously into the right axillary lymph nodes of 6-8-week-old BALB/c nude mice (5 mice/group). Tumor growth rate was evaluated by measuring tumor diameters and the tumor growth curve was recorded accordingly. Both the maximum (L) and minimum (W) length of the tumor were recorded using a slide caliper, and the tumor volume was calculated as ½LW^2. After 36 days, all the mice were sacrificed. All animal experiments were approved by the Institutional Review Board of Nanjing University of Chinese Medicine (Nanjing, China).

**Statistical analysis.** All experiments were performed in triplicate and representative data are shown from 3 separate experiments. Statistical analysis was performed using a t-test or one-way ANOVA and Spearman’s rank test using SPSS 16.0 software. A value of p<0.05 was considered to indicate a statistically significant difference.

**Results**

**miR-30a is frequently downregulated in breast cancer tissues.** To research the expression of miR-30a in breast cancer tissues and cell lines, we first compared the level of miR-30a expression in 20 paired breast tumor tissues and adjacent normal tissues by RT-qPCR (Table I); From the results, we confirmed that miR-30a expression was significantly downregulated in the tumor tissue compared to the adjacent normal tissue (p<0.0005, means ± SD) (Fig. 1).

**miR-30a inhibits the viability of breast cancer cells in vitro and in vivo.** The frequent downregulation of miR-30a in breast cancer tissues indicated that miR-30a may play a role in the development of breast cancer. In order to determine this, miR-30a mimic and negative control were successfully transfected into MCF-7 and MDA-MB-231 cells. At 48 h after transfection, we performed RT-qPCR to determine the expression level of miR-30a (Fig. 2A), and then a CCK-8 assay was performed. As shown in Fig. 2B and C, these assays confirm that the MCF-7 and MDA-MB-231 cells transfected with miR-30a mimic exhibited a significant decrease in cell proliferation compared to the cells transfected with the negative control. To further confirm the growth inhibitory effect of miR-30a on breast cancer cells in vivo, a xenograft tumor growth assay was performed. We found that the tumors from the mice injected with the miR-30a mimic-transfected cells were much smaller in size (Fig. 2F). In addition, as shown by the growth curve of the subcutaneous tumors, the tumors from the mice injected with the miR-30a mimic-transfected cells had a significantly lower growth rate compared to those from mice injected with the negative control-transfected cells (Fig. 2D). The tumor volume was also significantly lower in the nude mice injected with miR-30a mimic-transfected cells as compared to that of those injected with negative control-transfected cells (p<0.01; Fig. 2E).

**miR-30a induces the apoptosis of MCF-7 and MDA-MB-231 cells.** We used the rate of cellular apoptosis to determine the connection between miR-30a and apoptosis. In the MCF-7 cells, the upregulation of miR-30a increased apoptosis, as compared with the negative controls (Fig. 3A and C). Similarly, as shown in Fig. 3B in the MDA-MB-231 cells, miR-30a also increased apoptosis, as compared with the negative controls (Fig. 3B).
Figure 2. miR-30a inhibits breast cancer cell growth. (A) RT-qPCR was performed to confirm the transfection efficiency of miR-30a mimic in MCF-7 and MDA-MB-231 cells. (B and C) After transfection, the survival rates of MCF-7 and MDA-MB-231 cells were detected by cell counting kit-8 (CCK-8) assay. miR-30a inhibited breast cancer cell growth in vivo. (D and E) Tumor growth curve of miR-30a and control transfected MDA-MB-231 cells in nude mice (n=5/group, data are the means ± SD); **p<0.01 vs. control. (F) Images of the tumors from mice injected with miR-30a-overexpressing cells or controls are shown.

Figure 3. miR-30a induces the apoptosis of MCF-7 and MDA-MB-231 cells. (A and B) By flow cytometric analysis, the overexpression of miR-30a was shown to increase the apoptosis of breast cancer cell lines transfected with miR-30a mimics compared with the negative control-transfected cells. (C) Data represent the average of apoptotic cells, respectively, *p<0.05, means ± SD.
Results and Discussion

**miR-30a inhibits breast cancer cell migration and invasion in vitro.** To verify the effects of miR-30a on the metastatic ability of breast cancer cells, we transfected the MCF-7 and MDA-MB-231 cells with miR-30a mimic and observed a significant decrease in the number of migrated cells compared with the negative control (Fig. 4A and C). We also examined the effect of miR-30a on the invasion of breast cancer cells. The MCF-7 and MDA-MB-231 cells transfected with miR-30a mimic showed a significant decrease in the number of invading cells compared with the negative control (Fig. 4B and D).
ZHANG et al: miR-30a INHIBITS BREAST CANCER DEVELOPMENT

MDA-MB-231 cells transfected with miR-30a mimic exhibited a markedly inhibited invasive ability (Fig. 4B and D).

**Notch1 is a direct target gene of miR-30a in breast cancer.** To explore the mechanisms through which miR-30a executes its functions in breast cancer cells, we wished to determine the potential target of miR-30a in breast cancer. We found that Notch1 was a potential target of miR-30a, utilizing three independently bioinformatic algorithms (TargetScan, Pictar and microRNA). Thus, we examined the expression of Notch1 in the cells transfected with miR-30a mimic or negative control. The overexpression of miR-30a significantly decreased the protein expression of Notch1, as shown by western blot analysis (Fig. 5C). This indirectly confirmed that the expression level of Notch1 could be regulated by miR-30a. Additionally, computational analysis revealed that the 3'UTR of Notch1 contains a conserved binding site for miR-30a (Fig. 5A). To further confirm that miR-30a directly and negatively regulates Notch1 expression, we constructed luciferase reporter vectors that contained wild-type (Wt) and mutant (Mt) miR-30a target sequences of the Notch1-3'UTR. Co-transfection experiments in the breast cancer cells revealed that miR-30a significantly inhibited the luciferase activity of Wt Notch1-3'UTR reporter gene (p<0.05), but it failed to inhibit the Mt Notch1-3'UTR reporter gene (Fig. 5B). Thus, we verified that Notch1 was a direct target of miR-30a in breast cancer cells.

**Notch1 knockdown significantly inhibits breast cancer cell proliferation.** To confirm that Notch1 directly regulates the development of breast cancer, si-Notch1 was successfully transfected into MCF-7 cells (Fig. 6A). The transfection of si-Notch1 significantly inhibited breast cancer cell proliferation; however, compared with the cells transfected with si-Notch1 only, cell proliferation did not obviously change in the MCF-7 cells transfected with both si-Notch1 and miR-30a mimic, which implies that miR-30a inhibited cell proliferation via Notch1 (Fig. 6B).

**Notch1 inversely correlates with miR-30a expression in vivo.** To further confirm the correlation between Notch1 and miR-30a in tissues, we compared the level of Notch1 expression and miR-30a expression in 20 paired breast tumor tissues and adjacent normal tissues by RT-qPCR (Table I). The Notch1 expression levels were significantly increased compared to the adjacent normal tissues in breast cancer cells (Fig. 7B). Additionally, miR-30a expression was significantly downregulated compared to the adjacent normal tissues (Fig. 1). Based on the mRNA expression of Notch1 and miR-30a in breast tumor tissues, we revealed that there was a significant inverse correlation, as calculated by linear regression analysis (Spearman's rank test, r=-0.5934, p=0.009) (Fig. 7C). These data further confirmed that miR-30a targets Notch1.

**Discussion**

Accumulating studies have confirmed that miRNAs are aberrantly expressed in a variety of human cancers; similarly, they are involved in maintaining the balance of gene regulating networks that control cell expression (11-14). Some studies have reported that miRNAs not only play an important role in epigenetic changes, but also effectively regulate protein
miR-30a exhibited a significantly lower proliferation than the cancer. According to the cell proliferation assay, we discovered suggested that miR-30a plays a tumor-suppressive role in breast dysregulation of miR-30a in breast cancer tumorigenesis. This tissues compared with adjacent normal tissues, suggesting the data, miR-30a exhibited a reduced expression in breast tumor the development of breast cancer. Based on normal tissue tion, apoptosis, differentiation and tumor advance.

Notch plays a key role in breast cancer prolifera associated with cell transformation (32), cell cycle, progen signaling system in most multicellular organisms. Notch1 is be significantly associated with the prognosis of cancer (30,31). miR-30a has been shown to inhibit cell proliferation via Notch1 (Fig. 6B). From the tissue data, we found that Notch1 expression was significantly upregu...